{"id":"NCT00751790","sponsor":"Debiopharm International SA","briefTitle":"Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer","officialTitle":"A Multicenter, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2007-08","completion":"2007-08","firstPosted":"2008-09-12","resultsPosted":"2012-06-13","lastUpdate":"2014-07-25"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasm"],"interventions":[{"type":"DRUG","name":"triptorelin embonate (INN)","otherNames":[]}],"arms":[{"label":"Triptorelin","type":"EXPERIMENTAL"}],"summary":"Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment \\>90% of the patients would achieve and maintain castrate levels of serum testosterone.","primaryOutcome":{"measure":"Achievement of Castration and Maintenance of Castration","timeFrame":"at Day 29","effectByArm":[{"arm":"Triptorelin","deltaMin":97.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":1,"countries":["South Africa"]},"refs":{"pmids":["19888782"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":120},"commonTop":["Hot flush","Influenza","Hypertension","Back pain","Erectile dysfunction"]}}